Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | FABP3 | P05413 | 2/20 | 0.51 |
| ▸ | FABP4 | P15090 | 2/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838082 | 0.89 | HTR1A (0.49) | RAB9ASMN1; SMN2NPC1POLBTP53 | |
| SCHEMBL8983017 | 0.89 | HTR1A (0.48) | RAB9ASMN1; SMN2NPC1POLBRXRA | |
| SCHEMBL9356673 | 0.87 | RAB9A (0.56) | RAB9ASMN1; SMN2NPC1POLBTP53 | |
| SCHEMBL1388037 | 0.87 | RXRA (0.60) | RAB9ASMN1; SMN2NPC1POLBTP53 | |
| SCHEMBL691784 | 0.86 | MMP9 (0.51) | RAB9ASMN1; SMN2NPC1POLBABCB1 | |
| SCHEMBL1098255 | 0.86 | RAB9A (0.55) | RAB9ASMN1; SMN2NPC1POLBTP53 | |
| SCHEMBL14699947 | 0.86 | NPC1 (0.55) | RAB9ASMN1; SMN2NPC1POLBTP53 | |
| SCHEMBL1305739 | 0.85 | PTGER1 (0.61) | NPC1FABP3FABP4FABP5PTGER1 | |
| SCHEMBL23536856 | 0.84 | PTGER1 (0.60) | RAB9ANPC1RXRAPTGER1MRGPRX4 | |
| SCHEMBL5501764 | 0.84 | SCN9A (0.59) | RAB9ANPC1RXRAPTGER1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145425-B2 | Cephem compound having catechol group | SHIONOGI & CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| EP-2917223-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | Glaxo Group Limited (GB) | 2015-09-16 | — | — | EP | disclosed |
| US-9125950-B2 | Siderophore conjugate immunogenic compositions and vaccines | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150071961-A1 | SIDEROPHORE CONJUGATE IMMUNOGENIC COMPOSITIONS AND VACCINES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8834890-B2 | Siderophore conjugate immunogenic compositions and vaccines | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| US-20130102583-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2557082-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | Shionogi & Co., Ltd. (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-20120052087-A1 | Siderophore Conjugate Immunogenic Compositions and Vaccines | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2421529-A2 | SIDEROPHORE CONJUGATE IMMUNOGENIC COMPOSITIONS AND VACCINES | University of Florida Research Foundation, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123845-A2 | SIDEROPHORE CONJUGATE IMMUNOGENIC COMPOSITIONS AND VACCINES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102583-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | COMT, EZH1, SETD7 | RAB9A 2386/4885SMN1; SMN2 4252/4885NPC1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.